|
AstraZeneca PLC on Monday hailed phase 2 trial results of its cancer drug Enhertu, which it develops with Daiichi Sankyo Co Ltd. Astra, a Cambridge-based pharmaceutical firm, said analysis of the ongoing Destiny-PanTumor02 phase trial showed that Enhertu, or trastuzumab deruxtecan, met the pre-specified target for objective response rate ‘and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pretreated patients’. Cristian Massacesi, chief medical officer & Oncology chief development officer at AstraZeneca, said: ‘Enhertu has already demonstrated its potential to improve outcomes for patients with HER2 targetable breast, gastric and lung cancers, and these positive initial results in other tumour settings with significant unmet need are very encouraging. The Destiny-PanTumor02 results mark an important step forward in our understanding of the potential role of Enhertu across multiple HER2-expressing tumour types.’ The data will be shared with global regulatory authorities. Enhertu is approved in several countries for the treatment of forms of breast cancer. AstraZeneca shares were 0.2% higher at 10,808.50 pence each in London on Monday morning. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
